Cargando…

Corrigendum: Effect of 131 I with and without artificial liver support system in patients with Graves’ disease and severe liver dysfunction: A retrospective study

Detalles Bibliográficos
Autores principales:	Rao, Maohua, Wang, Yirui, Ren, Jianli, Chen, Yue, Zheng, Chenxi, Xiong, Yalan, Yan, Qingbo, Li, Shiying, Yuan, Gengbiao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9994179/ https://www.ncbi.nlm.nih.gov/pubmed/36909320 http://dx.doi.org/10.3389/fendo.2023.1136544

Ejemplares similares

Effect of (131)I with and without artificial liver support system in patients with Graves’ disease and severe liver dysfunction: A retrospective study
por: Rao, Maohua, et al.
Publicado: (2022)

Analysis of factors influencing the clinical outcome after surgery and (131)I therapy in patients with moderate-risk thyroid papillary carcinoma
por: Li, Yixuan, et al.
Publicado: (2022)

Diagnosis of thyroid disease using deep convolutional neural network models applied to thyroid scintigraphy images: a multicenter study
por: Zhao, Huayi, et al.
Publicado: (2023)

Poly (lactic-co-glycolic acid)-encapsulated iodine-131 nanoparticles fabricated with rhTSH induce apoptosis and immobilization of thyroid cancer cells
por: Fan, Yongzeng, et al.
Publicado: (2023)

Metabolic dysfunction-associated fatty liver disease is an early predictor for testosterone deficiency in aging men without metabolic syndrome
por: Liu, Chia-Chu, et al.
Publicado: (2023)

Contribution of Liver and Pancreatic Islet Crosstalk to β-Cell Function/Dysfunction in the Presence of Fatty Liver
por: López-Bermudo, Lucía, et al.
Publicado: (2022)

Hypothalamus-Pituitary-Adrenal Dysfunction in Cholestatic Liver Disease
por: Petrescu, Anca D., et al.
Publicado: (2018)

Gut Dysfunction and Non-alcoholic Fatty Liver Disease
por: Grabherr, Felix, et al.
Publicado: (2019)

Risk factors of hepatic dysfunction in patients with Graves’ hyperthyroidism and the efficacy of (131)iodine treatment
por: Wang, Renfei, et al.
Publicado: (2017)

Corrigendum: High Circulating Follicle-Stimulating Hormone Level Is a Potential Risk Factor for Renal Dysfunction in Post-Menopausal Women
por: Li, Qihang, et al.
Publicado: (2021)

Thyroid Storm Presenting as Acute Liver Failure in a Patient with Graves’ Disease
por: Hayat, Muhammad Hashim, et al.
Publicado: (2020)

Association of Metabolic Dysfunction-Associated Fatty Liver Disease and Liver Stiffness With Bone Mineral Density in American Adults
por: Li, Hejun, et al.
Publicado: (2022)

Sequential algorithm to stratify liver fibrosis risk in overweight/obese metabolic dysfunction-associated fatty liver disease
por: Lee, Chi-Ho, et al.
Publicado: (2023)

Asymmetric Graves’ Orbitopathy
por: Panagiotou, Grigorios, et al.
Publicado: (2020)

Corticosteroid Pulse Therapy for Graves' Ophthalmopathy Reduces the Relapse Rate of Graves' Hyperthyroidism
por: Le Moli, Rosario, et al.
Publicado: (2020)

Association of variant on the promoter of cluster of differentiation 74 in graves disease and graves ophthalmopathy
por: Liu, Yu-Huei, et al.
Publicado: (2020)

High-Sensitive CRP Correlates With the Severity of Liver Steatosis and Fibrosis in Obese Patients With Metabolic Dysfunction Associated Fatty Liver Disease
por: Zhu, Cuiling, et al.
Publicado: (2022)

Antioxidant Therapy in Graves’ Orbitopathy
por: Lanzolla, Giulia, et al.
Publicado: (2020)

Orbital Signaling in Graves’ Orbitopathy
por: Draman, Mohd Shazli, et al.
Publicado: (2021)

Preoperative preparation for Graves’ disease
por: Xu, Tianfeng, et al.
Publicado: (2023)

Liver-bone crosstalk in non-alcoholic fatty liver disease: Clinical implications and underlying pathophysiology
por: Zhao, Jiahui, et al.
Publicado: (2023)

Evaluation of Quality of Life in the Brazilian Graves' Disease Population: Focus on Mild and Moderate Graves' Orbitopathy Patients
por: Villagelin, Danilo, et al.
Publicado: (2019)

Effect of liver dysfunction on outcome of radioactive iodine therapy for Graves’ disease
por: Ze, Yuyang, et al.
Publicado: (2022)

Sphingolipids in the Heart: From Cradle to Grave
por: Kovilakath, Anna, et al.
Publicado: (2020)

Update on the surgical management of Graves’ orbitopathy
por: Baeg, Joonyoung, et al.
Publicado: (2023)

A Bidirectional Relationship Between Hyperuricemia and Metabolic Dysfunction-Associated Fatty Liver Disease
por: Yang, Chengzhang, et al.
Publicado: (2022)

Dimming the Powerhouse: Mitochondrial Dysfunction in the Liver and Skeletal Muscle of Intrauterine Growth Restricted Fetuses
por: Pendleton, Alexander L., et al.
Publicado: (2021)

Metabolic dysfunction-associated fatty liver disease and cardiovascular disease: A meta-analysis
por: Wen, Wen, et al.
Publicado: (2022)

The influence of thionamides on intra-thyroidal uptake of (131)I during radioiodine-131 treatment of Graves’ disease
por: Happel, Christian, et al.
Publicado: (2023)

The Effect of Inactivated SARS-CoV-2 Vaccines on TRAB in Graves’ Disease
por: Huang, LingHong, et al.
Publicado: (2022)

Corrigendum: Regulatory network and interplay of hepatokines, stellakines, myokines and adipokines in nonalcoholic fatty liver diseases and nonalcoholic steatohepatitis
por: Yang, Bing, et al.
Publicado: (2023)

Androgen dysfunction in non-alcoholic fatty liver disease: Role of sex hormone binding globulin
por: Song, Myeong Jun, et al.
Publicado: (2022)

The nonlinear relationship between thyroid function parameters and metabolic dysfunction-associated fatty liver disease
por: Hu, Yingying, et al.
Publicado: (2023)

The relationship between metabolic dysfunction-associated fatty liver disease and the incidence rate of extrahepatic cancer
por: Wei, Suosu, et al.
Publicado: (2023)

Metabolic dysfunction-associated fatty liver disease increased the risk of subclinical carotid atherosclerosis in China
por: Lei, Fang, et al.
Publicado: (2023)

Selenium in the Treatment of Graves’ Hyperthyroidism and Eye Disease
por: Lanzolla, Giulia, et al.
Publicado: (2021)

Mechanisms That Underly T Cell Immunity in Graves’ Orbitopathy
por: Fang, Sijie, et al.
Publicado: (2021)

Comprehensive Metabolomics Study in Children With Graves’ Disease
por: Xia, Qin, et al.
Publicado: (2021)

Cytokines as Targets of Novel Therapies for Graves’ Ophthalmopathy
por: Fallahi, Poupak, et al.
Publicado: (2021)

Current insights of applying MRI in Graves’ ophthalmopathy
por: Song, Cheng, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1ridik3eigsp7je60hr1v1f4j6